debt_leverage_profile
Near-zero debt; cash-funded clinical-stage biotech with no long-term debt obligations; 20% rate rise has negligible P&L impact
Inferred
Agent_Inference
interest_rate_sensitivity
Minimal; no floating-rate debt exposure; sensitivity limited to opportunity cost on cash holdings and higher equity discount rates
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
1) Chinese API manufacturing concentration for ibezapolstat synthesis; 2) U.S.-China trade restrictions on pharmaceutical precursor chemicals
Inferred
Agent_Inference
international_expansion_readiness
No current international revenue; sovereign currency devaluation exposure is effectively zero at this stage
Inferred
Agent_Inference
geographic_footprint
Operations entirely U.S.-based; no international revenue markets; currency devaluation risk is not applicable currently
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Single-source API manufacturer for ibezapolstat likely represents non-substitutable critical input; vendor lock risk is high
Inferred
Agent_Inference
business_model_type_primary
Drug development/pharma; not cloud-dependent for core operations; AWS termination would disrupt data systems but not halt clinical trials
Inferred
Agent_Inference
business_model_type_secondary
Pre-revenue clinical-stage biotech; secondary model is potential licensing or partnership deals upon Phase 3 success
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; standard clinical data management software; no deep proprietary cloud API integration identified
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; revenue model is drug commercialization/licensing, not an investment contract; equity is standard registered stock
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate HIPAA exposure from clinical trial patient data; limited GDPR risk given U.S.-only trials; CCPA compliance manageable at current scale
Inferred
Agent_Inference
antitrust_exposure_flag
Minimal antitrust risk; single-asset pre-revenue company with no market share in C. difficile treatment segment yet
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Currently 0% recurring revenue; 100% transactional/milestone-based; pre-commercialization stage with no product sales
Inferred
Agent_Inference
monetization_vector
Future monetization via drug sales (transactional/prescription-fill) or upfront licensing fees plus royalties from pharma partners
Inferred
Agent_Inference
pricing_architecture
Pricing will follow antibiotic reimbursement norms; ibezapolstat likely priced at premium vs. vancomycin (~$3K-$5K course) given CDI recurrence benefit
Inferred
Agent_Inference
pricing_power_rating
Moderate-high if superiority data confirmed; CDI has limited competition and high unmet need, supporting premium antibiotic pricing
Inferred
Agent_Inference
target_gross_margin_bracket
Pharma drug gross margins typically 70-85% post-commercialization; manufacturing cost of goods for antibiotics is relatively low
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider risk; prescription antibiotic with no freemium tier; compliance risk is patient adherence over short 10-day course
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is sublinear to headcount; commercialization can leverage CSO or partner sales force without proportional hiring
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of growth post-approval is primarily COGS and sales force; R&D spend drops sharply, improving operating leverage significantly
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; no franchise network
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC would be dominated by physician detailing and hospital formulary access costs; estimated CAC per prescriber ~$500-$2,000
Inferred
Agent_Inference
network_effect_present
No network effects; antibiotic adoption is driven by clinical evidence and formulary inclusion, not user-base size
Inferred
Agent_Inference
asset_efficiency_ratio
AI displacement risk is low; core value is proprietary DNA polymerase IIIC inhibitor IP, not a data or software process AI can replicate
Inferred
Agent_Inference
recession_resistance_tier
High recession resistance; C. difficile infection is non-discretionary acute care need; antibiotic demand is largely recession-insensitive
Inferred
Agent_Inference
customer_segment_primary
Hospital infectious disease departments and gastroenterology practices treating recurrent C. difficile infections
Inferred
Agent_Inference
customer_segment_secondary
Long-term care facilities and outpatient settings with high CDI prevalence; potential VA and federal health system contracts
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital allocated almost entirely to Phase 3 clinical trial execution; no legacy infrastructure drag; pure forward-state R&D investment model
Inferred
Agent_Inference
sec_cik
0001736243
High
SEC-EDGAR
ticker
ACXP
High
SEC-EDGAR